COVID-19 (Coronavirus)

Information about changes at hospitals and health centres can be found at


Updated - effective from 14 May 2020 until further notice. Under COVID-19 Alert Level 2 visitor access to health facilities continues to be restricted.– details for all facilities...

Last updated:
29 April 2020

Please remember, limiting our interactions with others is our best defence against COVID-19. Please don’t visit the hospital if you don’t need to. The following level 2 visitor restrictions are in place for all Canterbury DHB health facilities:

  • Visitors will be screened and asked to provide contact details upon arrival
  • Visitors who are unwell or have suspicion of COVID-19 will not be able to enter
  • Aged residential care: no visitors, however, family visits for palliative care residents who do not have COVID-19 will be considered on a case-by-case basis.

Specific and detailed visitor restrictions that apply to each hospital are available on our COVID-19 page.

Clinical drug trials

Official information request details

The number of clinical drug trials your DHB hosted in the 2017/2018 financial year + ongoing trials in 2019. Could figures please be broken-down by:

  1. The number of sponsored clinical trials involving devices and pharmaceuticals. 
  2. Phase 1 first-man-in clinical trials and phase 2a/b safety and efficacy trials, phase 3 broader efficacy trials and phase 4 post-marketing surveillance. And whether these trials are investigator-initiated or industry-sponsored commercially contracted trials.
  3. Investigator-initiated studies of non-therapeutic interventions, e.g. new diagnostics or new applications of existing diagnostics.
  4. Investigator-initiated observational studies including epidemiologic studies.
  5. Can you please also provide the aggregate income figure your DHB obtained from trials conducted in the 2017/2018 financial year.



Download (pdf, 300KB)

Back to Document Library

Page last updated: 26 June 2019

Is this page useful?